In preclinical models of IDH1-mut gliomas, long-term administration of DNA methyltransferase inhibitors (DNMTi), 5-azacitidine and decitabine, induced reduction of DNA methylation, glial differentiation, and a significant tumor growth inhibition in xenograft models [65,66]. The gene discussed is IDH1; the disease is central nervous system cancer.